γ′ Fibrinogen as a novel marker of thrombotic disease

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 11, 2012, Pages 1903-1909

  Farrell, David H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

fibrinogen; Cardiovascular disease; Inflammation; Risk marker; Thromboembolism; Thrombosis

Indexed keywords

FIBRINOGEN; GAMMA FIBRINOGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE MARKER; FIBRINOGEN BLOOD LEVEL; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; INFLAMMATION; PERIODONTITIS; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; METABOLISM;

BIOLOGICAL MARKERS; FIBRINOGEN; HUMANS; INFLAMMATION; THROMBOSIS;

EID: 84872897106     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0005     Document Type: Review

References (55)

1. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005;294:1799-809.
2. Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, et al. for the Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007;166:867-79.
3. de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 2010;36:7-17.
4. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102:1634-8.
5. Kim PY, Stewart RJ, Lipson SM, Nesheim ME. The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. J Thromb Haemost 2007;5:1250-6.
6. Falls LA, Farrell DH. Resistance of γA/ γ fibrin clots to fibrinolysis. J Biol Chem 1997;272:14251-6.
7. Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hematol 2007;14:236-41.
8. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007;5(Suppl 1):116-24.
9. Chung DW, Davie EW. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984;23:4232-6.
10. Fornace AJ Jr, Cummings DE, Comeau CM, Kant JA, Crabtree GR. Structure of the human γ-fibrinogen gene. Alternate mRNA splicing near the 3′ end of the gene produces γA and γB forms of γ-fibrinogen. J Biol Chem 1984;259:12826-30.
11. Lovely RS, Falls LA, Al-Mondhiry HA, Chambers CE, Sexton GJ, Ni H, et al. Association of γA/ γ′ fibrinogen levels and coronary artery disease. Thromb Haemost 2002;88:26-31.
12. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegård A, Farrell DH, et al. Elevated plasma fibrinogen γ′ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007;5:766-73.
13. Lovely RS, Kazmierczak SC, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, Farrell DH. γ′ fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem 2010;56:781-8.
14. Cheung EY, Uitte de Willige S, Vos HL, Leebeek FW, Dippel DW, Bertina RM, et al. Fibrinogen γ′ in ischemic stroke: a casecontrol study. Stroke 2008;39:1033-5.
15. Cheung EY, Vos HL, Kruip MJ, den Hertog HM, Jukema JW, de Maat MP. Elevated fibrinogen γ′ ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood 2009;114:4603-4.
16. Alexander KS, Madden TE, Farrell DH. Association between γ′ fibrinogen levels and inflammation. Thromb Haemost 2011; 105:605-9.
17. Collet JP, Nagaswami C, Farrell DH, Montalescot G, Weisel JW. Influence of γ′ fibrinogen splice variant on fibrin physical properties and fibrinolysis rate. Arterioscler Thromb Vasc Biol 2004;24:382-6.
18. Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing γ′ chains. Blood 2005;106:2730-6.
19. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ′ chains. Biochemistry 1996;35:10448-53.
20. Moaddel M, Farrell DH, Daugherty MA, Fried MG. Interactions of human fibrinogens with factor XIII: roles of calcium and the γ′ peptide. Biochemistry 2000;39:6698-705.
21. Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996;271:23121-5.
22. Lovely RS, Moaddel M, Farrell DH. Fibrinogen γ′ chain binds thrombin exosite II. J Thromb Haemost 2003;1:24-131.
23. Pospisil CH, Stafford AR, Fredenburgh JC, Weitz JI. Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem 2003;278:21584-91.
24. Pineda AO, Chen ZW, Marino F, Mathews FS, Mosesson MW, Di Cera E. Crystal structure of thrombin in complex with fibrinogen γ′ peptide. Biophysical Chem 2007;125:556-9.
25. Cooper AV, Standeven KF, Ariëns RA. Fibrinogen γ′-chain splice variant γ alters fibrin formation and structure. Blood 2003;102:535-40.
26. Gersh KC, Nagaswami C, Weisel JW, Lord ST. The presence of γ′ chain impairs fibrin polymerization. Thromb Res 2009;124:356-63.
27. Fredenburgh JC, Stafford AR, Leslie BA, Weitz JI. Bivalent binding to γA/ γ′-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem 2008;283:2470-7.
28. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin therapy. Proc Natl Acad Sci USA 1989;86:3619-23.
29. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
30. Drouet L, Paolucci F, Pasqualini N, Laprade M, Ripoll L, Mazoyer E, et al. Plasma γ′/γ′ fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor ? Blood Coagul Fibrinolysis 1999;10(Suppl 1):S35 - 9.
31. Uitte de Willige S, Standeven KF, Philippou H, Ariëns RA. The pleiotropic role of the fibrinogen γ′ chain in hemostasis. Blood 2009;114:3994-4001.
32. Lovely RS, Yang Q, Massaro JM, Wang J, D'Agostino RB Sr, O'Donnell CJ, et al. Assessment of genetic determinants of the association of γ′ fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol 2011;31:2345-52.
33. van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, et al. γ′/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost 2011;105:430-4.
34. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen γgene increases the risk for deep venous thrombosis by reducing plasma fibrinogen γ′ levels. Blood 2005;106:4176-83.
35. Mosesson MW, Hernandez I, Raife TJ, Medved L, Yakovlev S, Simpson-Haidaris PJ, et al. Plasma fibrinogen γ′ chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2007;5:62-9.
36. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen γ′ chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol 2007;139:494-503.
37. Lovely RS, Rein CM, White TC, Jouihan SA, Boshkov LK, Bakke AC, et al. γA/ γ′ fibrinogen inhibits thrombin-induced platelet aggregation. Thromb Haemost 2008;100:837-46.
38. Lancellotti S, Rutella S, De Filippis V, Pozzi N, Rocca B, De Cristofaro R. Fibrinogen-elongated γchain inhibits thrombininduced-platelet response, hindering the interaction with different receptors. J Biol Chem 2008;283:30193-204.
39. Mosesson MW. Update on antithrombin I (fibrin). Thromb Haemost 2007;98:105-8.
40. Amrani DL, Newman PJ, Meh D, Mosesson MW. The role of fibrinogen A α chains in ADP-induced platelet aggregation in the presence of fibrinogen molecules containing γ′ chains. Blood 1988;72:919-24.
41. Farrell DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen α and γchain sites in platelet aggregation. Proc Natl Acad Sci USA 1992;89:10729-32.
42. Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem 1994;269:226-31.
43. Nowak-Göttl U, Weiler H, Hernandez I, Thedieck S, Seehafer T, Schulte T, et al. Fibrinogen α and γ′ genes and factor V Leiden in children with thromboembolism: results from 2 family-based association studies. Blood 2009;114:1947-53.
44. Uitte de Willige S, Rietveld IM, De Visser MC, Vos HL, Bertina RM. Polymorphism 10034C > T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen γ′/ γA mRNA ratio. J Thromb Haemost 2007;5:1243-9.
45. Carter AM, Catto AJ, Kohler HP, Ariëns RA, Stickland MH, Grant PJ. α -Fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000;96:1177-9.
46. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariëns RA. Functional analysis of the fibrinogen A α Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003;107:2326-30.
47. Jood K, Danielson J, Ladenvall C, Blomstrand C, Jern C. Fibrinogen gene variation and ischemic stroke. J Thromb Haemost 2008;6:897-904.
48. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
49. van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, et al. Fibrinogen γ′ levels in patients with intracerebral hemorrhage. Thromb Res Epub 2011 Sept 12.
50. Grünbacher G, Weger W, Marx-Neuhold E, Pilger E, Köppel H, Wascher T, et al. The fibrinogen γ( FGG ) 10034C > T polymorphism is associated with venous thrombosis. Thromb Res 2007;121:33-6.
51. Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science 1945;101:520-1.
52. Petrera NS, Stafford AR, Leslie BA, Kretz CA, Fredenburgh JC, Weitz JI. Long range communication between exosites 1 and 2 modulates thrombin function. J Biol Chem 2009;284:25620-9.
53. Mosesson MW, Cooley BC, Hernandez I, Diorio JP, Weiler H. Thrombosis risk modification in transgenic mice containing the human fibrinogen thrombin-binding γ′ chain sequence. J Thromb Haemost 2009;7:102-10.
54. Weiler H. Mouse models of thrombosis: thrombomodulin. Thromb Haemost 2004;92:467-77.
55. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of PAR-1 on intact platelets. J Biol Chem 2001;276:4692-8.